morris-logo

Lymphoma is one of the most commonly occurring malignant tumors in dogs. Though treatable, the disease often recurs and spreads.

This study will determine the safety, efficacy and prognostic factors of a cancer-killing virus developed by researchers at the Mayo Clinic.

Researchers at the University of Tennessee have already determined a safe dosing protocol for this virus in healthy dogs, and this clinical trial will test the dosing in dogs with B-cell lymphoma.

Using state-of-the-art cancer imaging, the study team will determine how successfully the virus spreads to sites of cancer. They will also study the dogs’ immune responses to the virus.

FINAL RESULT:  Immunotherapy may revolutionize B-cell lymphoma treatment in dogs

Lymphoma is one of the most common types of malignant cancer. Several types of lymphoma are diagnosed in the
dog, but the majority (approximately 70 percent) arise from transformed B-cells. Unfortunately, in spite of many
advances in chemotherapy protocols, the prognosis for dogs with B-cell lymphoma has not changed significantly in
more than 30 years.

Passive immunotherapy, which uses molecules called antibodies to kill cancer cells, has revolutionized lymphoma
treatment in humans. Morris Animal Foundation-funded researchers at the University of Minnesota, in
collaboration with researchers at Idexx Laboratories, Elanco Animal Health, and Stanford University, investigated
whether or not this type of treatment could translate into helping dogs with cancer. Using recently developed
canine-specific antibodies, the research team evaluated the safety and efficacy of these antibodies in the treatment
of canine B-cell lymphoma. Antibodies were directed against two different targets on the cancer cells, and
investigators believed that a combination of these two antibodies would be effective in treating dogs with B-cell
lymphoma.

The researchers confirmed that the antibody combination promoted the killing of canine lymphoma cells in a
laboratory setting. The research team then used a pre-clinical model to test the combination. Highly encouraging
data suggested that this immunotherapy combination is both safe and effective in treating diffuse large B-cell
lymphoma. The next research step is to shepherd these antibody therapies through regulatory approval and into
canine clinical trials.

Lymphoma is a serious and common canine cancer, affecting dogs of any age or breed. Some breeds, such as
golden retrievers and boxers, have a historically higher risk for the disease. Other commonly affected breeds include
basset hound, Saint Bernard, Scottish terrier, bulldogs, Airedale, Weimaraner, Doberman pinscher, Labrador
retriever, English setter and Great Dane. If proven effective in clinical trials as passive immunotherapy, use of the
antibodies in this study could significantly improve treatment for all dogs with B-cell lymphoma. (D13CA-033)

AGSDCF Purpose

agsdcf_logo_smallThe American German Shepherd Dog Charitable Foundation, Inc. is a non-profit organization devoted to funding research projects that improve the health of the German Shepherd Dog.

We are grateful to the special dogs who have given their hearts and souls to make our daily lives happier. They ask nothing more than to be loved, fed, and their health needs met.

Your donations to this Foundation will help make future generations healthier and happier.

 

    

Contact us:  info@AGSDCF.com

Welcome  |  What AGSDCF Does  |  How You Help  |  AGSDCF Organization  |  Links  |  Photos  |  Donations  |  Site Map

Copyright 2000-2017 by the American German Shepherd Dog Charitable Foundation, Inc.

RocketTheme Joomla Templates